BridgeMD
New treatment option for Psoriatic Arthritis
Official title Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
ClinicalTrials.gov ID: NCT07286058
What this study is testing
What is Zasocitinib?
Zasocitinib is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for psoriatic arthritis.
Also referred to as TAK- 279, NDI-034858.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.
- Phase 3: a large, late-stage study
- Time commitment: about 2 years
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult...
- The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of...
- The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants assigned by chance to...
You likely can't join if
- Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of...
- Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or...
- The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective...
- The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the...
The study team makes the final eligibility decision.
Where it's taking place
- Fountain Valley, California, United States
- Thousand Oaks, California, United States
- Denver, Colorado, United States
- Hialeah, Florida, United States
- Plantation, Florida, United States
- Hagerstown, Maryland, United States
- Middleburg Heights, Ohio, United States
- Jackson, Tennessee, United States
- Baytown, Texas, United States
- Bellaire, Texas, United States
- Houston, Texas, United States
- Lubbock, Texas, United States
- Tsu, Mie, Mie-ken, Japan
- Chuo-ku, Tokyo, Japan
- Meguro-Ku, Tokyo, Japan
- Caguas, Puerto Rico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 2 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fountain Valley, California, United States; Thousand Oaks, California, United States; Denver, Colorado, United States; Hialeah, Florida, United States; Plantation, Florida, United States; Hagerstown, Maryland, United States and 10 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.